Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney transplant experiment halted before it began

NCT ID NCT05725421

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This study planned to test whether kidneys with small, low-risk tumors could be removed from donors, have the tumor taken out, and then be transplanted into patients with kidney failure. The goal was to increase the number of available donor kidneys. However, the study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For Donors: * Adults \> 50 years * Willing and able to understand and sign informed consent * Must have high-quality pre-operative cross-sectional imaging (CT or MRI) to determine tumor characteristics and perform parenchymal volume analysis for split renal function * Patient who is a candidate for partial nephrectomy for cT1a mass who understands that partial nephrectomy is standard of care for such mass but wishes to be an altruistic kidney donor (primary incentive is altruism) via radical nephrectomy with loss of the entire kidney. * Functional considerations: o Normal baseline renal function, with eGFR \> 80 ml/min/1.73 m2 * No proteinuria on urine dipstick (negative/trace considered negative) * Predicted new baseline GFR (NBGFR) following radical nephrectomy would be ≥ 45 * NBGFR would be calculated using previously described equation based on split renal function (SFR) and renal functional compensation (RFC) * NBGFR = global GFR x (SRFcontralateral from PVA) x 1.25 (average amount of RFC)2 * Tumor characteristics on pre-operative cross-sectional imaging: * Tumor appears well-encapsulated * Tumor appears amenable to ex-vivo partial nephrectomy with reconstruction that will leave ≥75% of the functioning parenchyma intact and well vascularized * Low risk of complications for the recipient after ex-vivo PN based on surgeon judgment * Tumor is cT1a which is defined as ≤ 4cm and confined * Reconstructed kidney is likely to provide NBGFR for the recipient of \>30 ml/min/1.73 m2. This can be estimated as (global GFR)(SRFipsilateral) x 0.75(estimate that at least 75% of the function will be saved during ex vivo tumor excision and reconstruction). Of note most such kidneys will experience some positive functional compensation but this might be mitigated by a small amount of functional loss related to ischemia. Most studies suggest that this will really be an underestimate of the final GFR in the recipient. For Recipients: * Age \>60 * Able to understand and willing to sign informed consent * Presence of ESRD or CKD5 with likely progression to ESRD * Does not have potential living donor * Not likely to receive a more "ideal" donor kidney due to significant comorbidities and/or age Exclusion Criteria: For Donors: * Known familial RCC syndrome * Functional considerations: o \< 50 years of age * Preoperative GFR \< 80 ml/min/1.73 m2 * Proteinuria on urine dipstick or urinalysis (≥1+ considered positive) * Predicted new baseline GFR (NBGFR) following radical nephrectomy would be \< 45 * NBGFR would be calculated using previously described equation based on split renal function (SFR) and renal functional compensation (RFC) * NBGFR = global GFR x (SRFcontralateral from PVA) x 1.25 (average amount of RFC)2 * Comorbidities with risk of deteriorating renal function: * Hypertension requiring three or more anti-hypertensives * Diabetes mellitus requiring insulin or with end organ damage * Morbid obesity * History of nephrolithiasis or other * Tumor characteristics on pre-operative cross-sectional imaging: o Tumor has infiltrative features * Tumor is \> 4cm (does not meet criteria for cT1a stage) * Regional lymphadenopathy, branch or main renal vein invasion, or other imaging findings suggestive of locally advanced disease * Kidney characteristics on pre-operative cross-sectional imaging: * More than one renal artery unless can be readily and safely reconstructed * More than one renal vein unless can be readily and safely reconstructed * Duplicated collecting system unless can be readily and safely reconstructed * High-risk features on renal mass biopsy (if obtained) or intraoperative pathology o Malignant non-RCC pathology o Rhabdoid or sarcomatoid differentiation o Grade 4 o Positive or concerning margins during tumor excision * Must be deemed appropriate living donor candidate per the standard living donor selection process at the Cleveland Clinic o All altruistic living donors undergo a complete evaluation by medical providers and social workers ensuring that they are appropriate candidates to undergo this procedure. This evaluation includes direct query into any history of psychiatric comorbidities and/or substance abuse. If present, this prompts a formal evaluation by psychiatry prior to confirmation of donor candidacy. For Recipients: • Traditional contraindications to kidney transplantation at the Cleveland Clinic would apply, including the following directly from the Transplant Care Pathway: * Active, untreated bacterial, fungal, or viral infections. Once treated, patients may be reconsidered. Patients with human immunodeficiency virus (HIV)14 or chronic hepatitis15 infections will be evaluated on an individual basis. * Active malignancy, except non-melanoma skin cancer and other selected low-grade, low-stage cancers (e.g., bladder, kidney, prostate). The American Society of Transplant (AST) clinical practice guidelines published in 2001 are dated. Improved methods of cancer prognostication are available on a cancer-specific basis.16 An acceptable disease-free waiting period may be needed prior to transplantation depending on the cancer type (stage/grade) and treatment modality. Expert opinion from an oncological specialist may be needed to facilitate decisions about wait-listing or performance of a transplant. * Medical non-adherence, substance abuse or behaviors leading to a failure to achieve a therapeutic physician/transplant team-patient alliance. * Life expectancy of less than five years independent of renal disease. * Advanced circulatory disease (cardiac, cerebral, peripheral), pulmonary disease or other non-renal conditions such that transplantation would pose a significant risk for morbidity/mortality. * Obesity with body mass index (BMI) \> 38, or an abdominal wall configuration that in the judgment of the evaluating surgeon poses undue complication risk. * Active nicotine abuse (in any form). * Poor functional status independent of renal disease. * Considering the average waiting times for a deceased donor kidney is more than 3 years, only transplant candidates 72 years or younger will be accepted for evaluation. Suitable candidates may remain on the waiting list up to the age of 75-year-old. They will be delisted if no transplantation has occurred. * Cumulative burden of disease defined as multiple medical conditions that on their own may not preclude listing but that in combination are deemed not suitable by the transplant selection committee.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.